1. Delivering clinical research to make patients, and the NHS, better Skin SSG – Research 18 th June 2015 Dr Toby Talbot, Consultant Oncologist Wendy Cook, Research Delivery Manager

2. South West Peninsula CRN HospitalSize Yeovil District Hospital NHS Foundation Trust Small Acute Taunton and Somerset NHS Foundation Trust Medium Acute Northern Devon Healthcare NHS Trust Small Acute Royal Devon and Exeter NHS Foundation Trust Large Acute South Devon Healthcare NHS Foundation Trust Medium Acute Plymouth Hospitals NHS TrustLarge Acute Royal Cornwall Hospitals NHS TrustLarge Acute

3. Division 1- Cancer - Contacts Duncan Wheatley, Clinical Specialty Lead duncan.wheatley@rcht.cornwall.nhs.uk 01872 258312duncan.wheatley@rcht.cornwall.nhs.uk Toby Talbot, Sub specialty lead toby.talbot@nhs.net 01872 258314 toby.talbot@nhs.net Wendy Cook, Research delivery manager wcook1@nhs.net 01392 406995 wcook1@nhs.net Ann Courtman, Administrator ann.courtman@nhs.net ann.courtman@nhs.net 01392 406966 3

4. NIHR Cancer Research Objectives Increase the opportunities for cancer patients to take part in research studies, regardless of where they live Develop an action plan to increase access in each subspecialty (e.g by opening studies, increasing awareness and forming referral pathways for access to research) 4

5. NIHR Cancer Research Objectives Increase the number of cancer patients participating in studies, to support the national target of 20% cancer incidence –SW Peninsula Cancer Incidence 12,580 –20% = 2,516 pts –Current performance – 1535pts 12.2% Increase the number of cancer patients participating in interventional trials, to support the national target of 7.5% cancer incidence –7.5% = 944 pts –Current performance – 714pts 5.7% This is measured on 12 months data from ODP 5

6. What we need to achieve in each subspecialty group 13 named cancer sub specialty leads with a defined portfolio of studies Highlight, promote studies Promote referral pathways throughout the network Research Subspecialty Lead –Participate in national meetings to collaborate with other sub-speciality leads, identify studies to bring to the region –Connection with CSG’s, feedback re sub specialty portfolio and availability of trials for all. 6

7. Melanoma Recruitment National Overview Data from Portfolio ODP – Cut off 15/05/15

8. Melanoma Recruitment National Overview Data from Portfolio ODP – Cut off 15/05/15 CRN2013/20142014/2015 East Midlands 4921 Eastern 7083 Greater Manchester 5114 Kent, Surrey and Sussex 137 North East and North Cumbria 11 North Thames 4727 North West Coast 9076 North West London 71 South London 15144 South West Peninsula 4523 Thames Valley and South Midlands 4742 Wessex 6434 West Midlands 5230 West of England 2833 Yorkshire and Humber 122250

9. SWP Melanoma Recruitment by Trust Data from Portfolio ODP – Cut off 15/05/15

10. Melanoma 2014/2015 Studies Data from SWP RAG Report– Cut off 05/05/15 AcronymStudy TypeTrust Study Status Total Recruitment 2014/2015 Recruitment Target BRF115532Commercial Royal Devon and Exeter NHS Foundation Trust Closed505 AVAST-MNon-Commercial Royal Cornwall Hospitals NHS Trust Closed2022 CANC-3574 - Nivolumab (BMS-936558) in Stage III (unresectable) or stage IV Melanoma (CA209-172) Commercial Royal Cornwall Hospitals NHS Trust Open003 NCRN398 IMAGE: Observational Study in Patients with Unresectable or Metastatic Melanoma CommercialPlymouth Hospitals NHS TrustClosed1343 NCRN398 IMAGE: Observational Study in Patients with Unresectable or Metastatic Melanoma Commercial Royal Cornwall Hospitals NHS Trust Closed27954 NCRN398 IMAGE: Observational Study in Patients with Unresectable or Metastatic Melanoma Commercial Royal Devon and Exeter NHS Foundation Trust Closed706 NCRN398 IMAGE: Observational Study in Patients with Unresectable or Metastatic Melanoma Commercial Taunton and Somerset NHS Foundation Trust Closed823 NCRN398 IMAGE: Observational Study in Patients with Unresectable or Metastatic Melanoma Commercial Yeovil District Hospital NHS Foundation Trust Closed31Unknown NCRN442 BRIM 8: Vemurafenib in adjuvant melanoma Commercial Royal Cornwall Hospitals NHS Trust Open005 NCRN492 - NEMO-MEK162 vs Dacarzabine in NRAS mutation postive melanoma patients Commercial Royal Cornwall Hospitals NHS Trust Open223 The Melanoma Lifestyle StudyNon-Commercial Taunton and Somerset NHS Foundation Trust Closed18172 The Melanoma Lifestyle StudyNon-Commercial Yeovil District Hospital NHS Foundation Trust Closed122Unknown UKMCC-01Non-Commercial Royal Devon and Exeter NHS Foundation Trust Open112 UKMCC-01Non-Commercial Taunton and Somerset NHS Foundation Trust Open002

11. Portfolio maps link http://csg.ncri.org.uk/portfolio-maps/ Moving forward the Network aim is to map sites open to studies on the portfolio maps This is large piece of work and will take some time 11